Understanding Brainstem Glioma: Diagnosis, Treatment, and Support
Receiving a brainstem glioma diagnosis, whether for yourself or a loved one, can feel overwhelming and certainly life-changing. It is a rare condition, and many people hearing the term for the first time are searching for answers, clarity, and hope. This page offers clear information about brainstem gliomas, how brainstem tumours like these are treated and where patients and families can get help.
What Is Brainstem Glioma?
A glioma is a type of brain or spinal cord tumour that begins in glial cells, which support and protect nerve cells. When this occurs in the brainstem, it is called a brainstem glioma.
The brain stem is made up of the midbrain, pons and medulla. It is the lowest part of the brain and connects to the spinal cord, just above the base of the neck. The brain stem controls vital functions such as breathing, heart rate and blood pressure, and the nerves and muscles used in seeing, hearing, walking, talking and eating.
Brain stem gliomas account for 10-20% of childhood brain tumours and commonly affect children between the ages of 5 to 10.
Types of Brainstem Gliomas
While the term “brainstem glioma” is often used, it is not a formal diagnosis. It describes a broad group of brainstem tumours that arise in the brainstem and differ in both pathology and prognosis. Most brainstem gliomas occur in children, but they can also develop in adults. Each case requires a tailored approach.
These tend to be slower growing and more localised. They may be surgically treated depending on the tumour location.
Historically used to describe aggressive childhood gliomas of the pons. Most cases are now classified under the World Health Organization (WHO) entity diffuse midline glioma (DMG), H3 K27-altered (WHO grade 4), reflecting the underlying molecular change.
A grade 4 tumour defined by an H3 K27 alteration, usually arising in midline structures such as the pons, thalamus, or spinal cord. It is highly aggressive and most common in children.
Adult brainstem gliomas are uncommon and biologically diverse, ranging from low grade to high grade. Prognosis varies by subtype.
Pontine gliomas arise in the pons and may be diffuse or focal, with different management and outcomes (e.g., all DIPGs are pontine gliomas, but not all pontine gliomas are DIPGs or DMGs).
Focal midbrain gliomas, including tectal tumors, are relatively rare and often amenable to conservative management or surgery when indicated.
Brainstem Glioma Symptoms
The signs and symptoms of brainstem glioma depend on the tumour’s location, size, and whether it is focal or diffuse. Some develop gradually, while others appear suddenly.
Common symptoms may include:
- Trouble with balance and coordination
- Weakness or numbness in the arms, legs or face
- Difficulties with swallowing, slurred speech and communicating at times
- Problems with vision or hearing
- Headaches, vomiting, nausea, or morning sickness due to increased pressure
- Drowsiness, personality or behaviour changes
Because the nervous system is complex, brainstem tumours can lead to cranial nerve palsies or even multiple cranial nerve palsies, which affect facial muscles, eye movement, and speech. Neurologists also look for long tract signs, such as weakness on one side of the body, which help identify brainstem lesions.
How Is Brainstem Glioma Diagnosed?
Doctors begin by assessing signs and symptoms and taking a full history. Neurological exams test balance, reflexes, coordination, and facial movements.
The main diagnostic tool is magnetic resonance imaging (MRI), which gives detailed pictures of the brain and spinal cord. In some cases, stereotactic biopsy may be used to obtain tumour cells for analysis, though this carries risks due to the sensitive location.
Other imaging methods, such as CT scans, may also be used. Diagnosis considers the tumour grade (low vs high-grade glioma) and other prognostic factors that affect treatment options.
Treatment Options For Brainstem Glioma
Treatment for brain stem tumours depends on whether the glioma is focal or diffuse, its tumour grade, and the age and health of the patient.
Surgery
For focal gliomas, surgical resection may be possible. However, DIPG and other diffuse intrinsic brainstem gliomas are not resectable.
Radiation therapy
The most common treatment, used to slow growth and improve quality of life. Sometimes described as radiation treatment, this approach can help relieve symptoms.
Chemotherapy
While standard chemotherapy drugs are sometimes used, effectiveness varies. They are more often part of clinical trials. However, in the U.S., Dordaviprone is now approved for recurrent H3 K27M-mutant DMG. Access elsewhere varies.
Stereotactic radiosurgery
A targeted form of radiation that may help in specific cases of focal or low-grade glioma. It is not used for diffuse intrinsic disease.
Additional treatment
Because neuro-oncology research is evolving, many families consider clinical trials to access investigational therapies, including targeted agents and immunotherapies. Standard care for diffuse brainstem glioma remains radiotherapy. Use of targeted or immune therapies is largely confined to trials and depends on eligibility, molecular findings, and patient factors.
What Is the Survival Rate for Brainstem Glioma?
Survival rates vary depending on tumour type:
- Children with focal gliomas or low-grade tumours may have a favourable prognosis if treatment is possible.
- Patients with diffuse midline glioma, H3 K27-altered (DMG, WHO grade 4) have poorer survival. Median survival is about 9 to 12 months. Many tumours once called DIPG fall into this category when tested.
Other prognostic factors, such as age, tumour grade, and whether the glioma is operable, all play a role. Doctors may also use data from neuro-oncology research to guide discussions. Every patient’s journey is unique, and doctors will consider many factors beyond just statistics when discussing prognosis.
Can Brainstem Glioma Be Cured?
Many wonder, is brainstem glioma curable? Currently, there is no known cure for diffuse midline glioma, H3 K27-altered. Radiotherapy is the standard treatment. This helps improve symptoms for a time, however, median survival is about 9 to 12 months.
Some low-grade tumours or exophytic tumours that grow outward may be operable or managed with cerebrospinal fluid (CSF) diversion.
Clinical trials are ongoing, including targeted agents and immunotherapies for DMG. These options are largely investigational and depend on eligibility and molecular findings.
Living With Brainstem Glioma
Coping with this diagnosis means managing more than medical treatments. Families and patients often deal with changes to mobility, communication, and daily activities.
Support may include:
- Rehabilitation, physiotherapy, occupational therapy, and speech therapy.
- Symptom control, for example steroids, for edema with monitoring for side effects such as weight gain, mood change, and glucose rise.
- Management of complications, for example hydrocephalus from fourth-ventricle obstruction, and bulbar problems from medullary involvement.
- Emotional and psychological support for both patients and carers.
- Palliative care may also be introduced at any stage, not just the end of life. Its focus is on easing symptoms, supporting families, and improving quality of life alongside other treatments.
Those newly diagnosed may experience shock and uncertainty. Guidance from a dedicated care team can help address mild symptoms early and adjust to changes over time.
Support, Research, and Hope for the Future
Living with brainstem glioma is not something anyone should go through alone. Support services, including counselling, carer networks, and patient groups, play an essential role in helping families cope.
Research is advancing worldwide in brainstem gliomas. Key areas include diffuse midline glioma, H3 K27-altered, paediatric pontine disease, and adult brainstem gliomas. Studies focus on tumour biology, molecular profiling, image-guided biopsy, and investigational therapies, including targeted and immune approaches. In the US, Dordaviprone now has accelerated approval for recurrent H3 K27M-mutant DMG; use and access vary by region.
At Cure Brain Cancer Foundation, we are committed to supporting innovation and funding breakthroughs in neuro-oncology. Explore the research we’re funding to help drive breakthroughs in how we understand and treat brain cancer. You can also learn more about other types of brain cancer to give you the clarity you need.
Newly diagnosed or caring for a loved one with brainstem glioma?
Visit our Support Hub for practical advice and useful information to help you on your journey.
Disclaimer: All Cure Brain Cancer Foundation website content is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. You should seek your own medical advice from your doctor or other qualified health professionals.
References
- Medscape. Brainstem Gliomas: Practice Essentials
- UCSF Brain Tumor Center. Brainstem Glioma
- Brainstem Glioma – an overview | ScienceDirect Topics
- Brainstem glioma | Radiology Reference Article | Radiopaedia.org
- Childhood Astrocytomas and Other Gliomas Treatment (PDQ®) – NCI
- Childhood Glioma (Including Astrocytoma) – NCI
- Children’s Cancer Centre : Brain Stem Glioma
- Coleman C, Chen K, Lu A, Seashore E, Stoller S, Davis T, Braunstein S, Gupta N, Mueller S. Interdisciplinary care of children with diffuse midline glioma. Neoplasia.
- Diffuse midline glioma, H3 K27-altered | Radiology Reference Article | Radiopaedia.org
- Focal brainstem glioma | Radiology Reference Article | Radiopaedia.org
- Noon A, Galban S. Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas. Neoplasia. 2023 Jun;40:100899. doi: 10.1016/j.neo.2023.100899. Epub 2023 Apr 6. PMID: 37030112; PMCID: PMC10119952.
- Reyes-Botero G, Mokhtari K, Martin-Duverneuil N, Delattre JY, Laigle-Donadey F. Adult brainstem gliomas. Oncologist. 2012;17(3):388-97. doi: 10.1634/theoncologist.2011-0335. Epub 2012 Mar 1. PMID: 22382458; PMCID: PMC3316925.
- Steroids for brain cancer
- Sun, T., Xu, Y., Pan, C., Liu, Y., Tian, Y., Li, C., … & Zhang, L. (2020). Surgical treatment and prognosis of focal brainstem gliomas in children: A 7 year single center experience. Medicine, 99(36), e22029.
- Understanding Brain Tumours
- Valvi S, Manoharan N, Mateos MK, Hassall TE, Ziegler DS, McCowage GB, Dun MD, Eisenstat DD, Gottardo NG, Hansford JR. Management of patients with diffuse intrinsic pontine glioma in Australia and New Zealand: Australian and New Zealand Children’s Haematology/Oncology Group position statement. Med J Aust. 2024 Jun 3;220(10):533-538. doi: 10.5694/mja2.52295. Epub 2024 May 3. PMID: 38699949.